Home >> Tag Archives: PreludeDx—

Tag Archives: PreludeDx—

Study: DCISionRT predicts radiation therapy benefit

Aug. 9, 2018—Prelude Corp. announced that Clinical Cancer Research published results from a large cross-validation study of DCISionRT in patients with ductal carcinoma in situ (Bremer T, et al. Epub ahead of print July 27, 2018. doi:10.1158/1078-0432.CCR-18-0842). The multisite study demonstrated that DCISionRT was a strong predictor of radiation benefit and was able to identify patients with significantly elevated recurrence ...

Read More »

PreludeDx unveils predictive assay for DCIS

Jan. 16, 2018—PreludeDx announced in an oral presentation at the San Antonio Breast Cancer Symposium, held in December, the results from the SweDCIS randomized trial. The results confirmed that DCISionRT, the DCIS Test, predicts which patients with ductal carcinoma in situ will benefit from radiation therapy after breast conserving surgery. The results, shared by SweDCIS principal investigator, Fredrik Wärnberg, MD, ...

Read More »